GSK and Hengrui Pharma Forge $500 Million China Collaboration, Including PDE3/4 Inhibitors
1. GSK paid $500 million upfront for global development rights to Hengrui’s portfolio of up to 12 early-stage assets. 2. ...
Tag: GSK
GSK: Depemokimab Monoclonal Antibody Reduces Asthma Attacks
Depemokimab was shown to reduce exacerbations in patients with severe asthma. The proportions of adverse events of Depemokimab and the ...
GSK’s Jemperli in combination with chemotherapy shows improved overall survival in patients with endometrial cancer.
Jemperli in combination with chemotherapy showed a 31% reduction in the risk of death and a 16.4-month improvement in median ...
